Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile^® Technology. VT-1161 has been shown in preclinical studies to potently inhibit a wide range of fungal pathogens causing human disease, while maintaining a very significant safety margin. The initial Phase 1 study, a single-ascending dose trial in healthy volunteers, is currently being conducted in the United States.

“We are very excited that VT-1161 has begun the clinical stage of development”

"We are very excited that VT-1161 has begun the clinical stage of development," said Robert Schotzinger, M.D., Ph.D., President and Chief Executive Officer of Viamet. "There is a surprising lack of novel compounds in development to treat fungal infections in humans. Current antifungal therapies suffer to varying degrees from a lack of antifungal spectrum, poor safety profiles (e.g., liver toxicity, drug interactions), and lack of flexible dosing strategies. In preclinical studies, VT-1161 has been shown to be one of the most potent antifungal agents ever discovered against a wide range of pathogenic fungi which cause diseases such as invasive candidiasis and onychomycosis. However, despite its high potency, VT-1161 has also exhibited a very impressive safety and pharmacokinetic profile."

VT-1161 is one of several small molecule agents currently under development at Viamet Pharmaceuticals for the treatment of fungal infections in humans. VT-1129 is a potent and safe, oral, preclinical development candidate for the treatment of cryptococcal meningitis. Several additional molecules are in early-stage development for the treatment of invasive mold infections.

Source Viamet Pharmaceuticals, Inc.